Hundemer GL, Talarico R, Tangri N, et al. - Researchers conducted this population-based, retrospective cohort study to determine hyperkalemia recurrence risk based on outpatient pharmacologic alterations after an episode of renin-angiotensin-aldosterone system inhibitor (RAASi)-related hyperkalemia. Participants were 49,571 older adults (mean age 79 years) who experienced hyperkalemia (potassium ≥ 5.3 mEq/L) while receiving a RAASi and were split as follows: no intervention, RAASi discontinuation, RAASi dose reduction, new diuretic, diuretic dose increase, or sodium polystyrene sulfonate within 30 days. Relative to no intervention (35%, referent), lower cumulative incidence of recurrent hyperkalemia was noted in relation to RAASi discontinuation, whereas no difference was evident with RAASi dose reduction, new diuretic, or diuretic increase and a higher incidence with sodium polystyrene sulfonate. Findings revealed that RAASi discontinuation in older adults with RAASi-related hyperkalemia was related to the lowest risk of recurrent hyperkalemia, with no apparent increment in short-term risks for cardiovascular events or all-cause death.